(Q58908789)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18936789%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

title

Is intravenous iron supplementation with erythropoiesis-stimulating agents beneficial in cancer patients with anemia? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18936789%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18936789%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

21 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18936789%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Oncology

24 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18936789%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18936789%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18936789%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

688-689

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18936789%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/ncponc1252

24 December 2019

exact match

0 references

cites work

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1252

7 January 2021

Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1252

7 January 2021

Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1252

7 January 2021

Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1252

7 January 2021

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1252

7 January 2021

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1252

7 January 2021

The role of iron supplementation during epoietin treatment for cancer-related anemia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1252

7 January 2021

Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1252

7 January 2021

Identifiers

DOI

10.1038/NCPONC1252

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18936789%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

24 December 2019

1048112590

0 references

Fatcat ID

release_bjknxtitxzax5a7fdzm22d4o6e

0 references

1 reference